Preclinical and Translational Development
Celgene Cellular Therapeutics,USA
Uri Herzberg received his B.Sc. and D.V.M. degrees from Washington State University in 1991 and his Ph.D. in veterinary Biology and Neuroimmunology in 1995 from the University of Minnesota. Following a Post Doctoral Fellowship at the NIH, he joined Cytotherapeutics and then Acorda Therapeutics where he established the company’s in-vivo facility and managed all the company’s in-vivo operations. In 2002 he joined Neurogen Corporation, and led the pain biology program. That program lead to a licensing deal with Merck and a compound that advanced to Phase IIb. In 2002 he joined Johnson and Johnson as a Principal Scientist, leading several projects for post surgical outcomes, and drug-device combination products. While at J&J he advanced to a Research Fellow and also led an osteoarthritis project, a consumer product project and efforts in drug delivery. During that time he received his MBA in pharmaceutical development from Fairleigh Dickinson University. In 2010 Uri joined Celgene as Associate Director for Translational Science. His currently serves as the Director of Preclinical and Translational Development. He is primary or co-author for 22 peer reviewed original manuscripts and has over 15 patent applications and patents. His areas of expertise are comparative biology and veterinary medicine of laboratory animals, neuroscience and neuroimmunology, inflammation and chronic pain. He is an ad hoc reviewer for the Small Business Innovative Research Grants – NIH, Special Section on Neuropharmacology and Neuroimmunology. He is also a reviewer for the following journals: Physiology and Behavior, Pain and The Journal of Pain.
Uri Reseach focuses on Comparative Biology and Veterinary Medicine of Laboratory Animals, Neuroscience and Neuro immunology, Inflammation and Chronic Pain